FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, reviews the venous thromboembolism (VTE) data behind ...

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, ...

Sarah Cannon's Kelsey Martin, APRN, AOCNP, discusses managing toxicities, nursing collaboration, and tailored treatment sequencing in frontline mTNBC. In an era of rapid oncology advancements, ...

Christine Magnus Moore, RN, BSN, CPON has worked in the nursing field for over twenty-five years, with more than fourteen years in oncology. She has a Master’s Certification in caring for teenagers ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly three decades. Surbhi Sidana, MD, discusses how the FDA-approved oral ...

Chasity Washington MPH, CHES | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

Having recently moderated a case-based roundtable discussion on triple-negative breast cancer, Iorio shares her clinical ...

C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care. Physician ...

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic ...